BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target

BTIG analyst Julian Harrison has reiterated a Buy rating on Spyre Therapeutics (NASDAQ: SYRE) and maintained a price target of $121 for the stock. No additional financial figures or strategic changes were mentioned in the article.